The head of Cipla, $ 325-million Indian pharmaceutical company and seller of cheap AIDS drugs in South Africa, have to decide what to do with the future of Cipla's. With India ready to comply with international patents in two years, much of the product line Cipla could become unsalable (given that it is based on the product is protected by patents in developed countries). Describes the role of a global pharmaceutical Cipla forcing companies to reduce the price of AIDS drugs. "Hide
by Rohit Deshpande Source: Video Supplement 7 minutes. Publication Date: February 27, 2007. Prod. #: 507705-VID-ENG
Related Case Solutions & Analyses:
Northwest Community Ventures Fund
Neverfail Computing
Jamie Dimon and Bank One (A)
Colonial Homes
The Space Shuttle Challenger Teleconference
FARGO HEALTH GROUP: MANAGING THE DEMAND FOR MEDICAL EXAMINATIONS USING PREDICTIVE ANALYTICS
Harley Davidson Motor Company
Baria planning solution incorporation: Fixing the sales process
EUCALYPTUS SAND HILL HOTEL AND OFFICE DEVELOPMENT PROJECT
Parkin Laboratories Sales Force Effectiveness
